Were Analysts Bearish China Cord Blood Corporation (NYSE:CO) This Week?

December 8, 2017 - By Linda Rogers

 Were Analysts Bearish China Cord Blood Corporation (NYSE:CO) This Week?
Investors sentiment increased to 2.33 in 2017 Q2. Its up 0.89, from 1.44 in 2017Q1. It increased, as 4 investors sold China Cord Blood Corporation shares while 5 reduced holdings. 15 funds opened positions while 6 raised stakes. 6.75 million shares or 4.83% more from 6.44 million shares in 2017Q1 were reported.
Credit Suisse Ag holds 906,114 shares. Commonwealth Of Pennsylvania School Empls Retrmt stated it has 40,870 shares or 0.01% of all its holdings. Lucus Advsrs Limited has invested 0.49% in China Cord Blood Corporation (NYSE:CO). The United Kingdom-based Barclays Public Ltd has invested 0% in China Cord Blood Corporation (NYSE:CO). Parametrica Mgmt owns 15,700 shares. 244,388 are owned by Lazard Asset Mgmt Ltd Liability Com. Pnc Financial Svcs Gp has invested 0% of its portfolio in China Cord Blood Corporation (NYSE:CO). Service Automobile Association stated it has 0.01% of its portfolio in China Cord Blood Corporation (NYSE:CO). Acadian Asset Mgmt Ltd Liability Company accumulated 622,995 shares. Arrowstreet Capital Ltd Partnership invested in 0% or 52,001 shares. Brandes Inv Prns L P, California-based fund reported 39,542 shares. Creative Planning reported 0% stake. 1,000 are held by Comml Bank Of Montreal Can. State Street has 0% invested in China Cord Blood Corporation (NYSE:CO) for 30,056 shares. Fny Managed Accounts Ltd owns 350 shares or 0.03% of their US portfolio.

China Cord Blood Corporation (NYSE:CO) Ratings Coverage

Among 2 analysts covering China Cord Blood (NYSE:CO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. China Cord Blood had 4 analyst reports since August 21, 2015 according to SRatingsIntel. The firm earned “Sector Perform” rating on Friday, February 5 by Howard Weil. TH Capital maintained it with “Neutral” rating and $7.25 target in Friday, August 21 report. On Friday, August 28 the stock rating was maintained by Roth Capital with “Hold”. Below is a list of China Cord Blood Corporation (NYSE:CO) latest ratings and price target changes.

The stock decreased 2.09% or $0.22 during the last trading session, reaching $10.31. About 200,305 shares traded. China Cord Blood Corporation (NYSE:CO) has risen 28.22% since December 8, 2016 and is uptrending. It has outperformed by 11.52% the S&P500.

China Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company has market cap of $1.17 billion. The firm offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. It has a 28.56 P/E ratio. As of March 31, 2017, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province.

More notable recent China Cord Blood Corporation (NYSE:CO) news were published by: Seekingalpha.com which released: “China Cord Blood’s (CO) Management on Q2 2018 Results – Earnings Call Transcript” on November 21, 2017, also Seekingalpha.com with their article: “China Cord Blood (CO) Q3 2017 Results – Earnings Call Transcript” published on February 27, 2017, Prnewswire.com published: “China Cord Blood Corporation Announces Executive Change” on March 31, 2017. More interesting news about China Cord Blood Corporation (NYSE:CO) were released by: Seekingalpha.com and their article: “China Cord Blood (CO) on Q4 2017 Results – Earnings Call Transcript” published on June 22, 2017 as well as Prnewswire.com‘s news article titled: “China Cord Blood Corporation Announces Results of 2017 Annual General Meeting” with publication date: December 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.